While intranasal administration of hBD-2 even in a therapeutic setting lessens pulmonary inflammation in models of both steroid sensitive and steroid refractory asthma, treatment efficacy in those models was mirrored by diminished cell influx (27). The gene discussed is DEFB4A; the disease is asthma.